How Severity Weighting Changes What a Health System Will Pay

A severity modifier is the rule that lets a health system pay more for a single unit of health when the disease being treated is severe than when it is mild. It works by multiplying the health a treatment produces before that health is set against its cost, so a therapy for a devastating illness can pass the same value test at a higher price. In England, the National Institute for Health and Care Excellence (NICE) does this with a modifier that multiplies health gains by 1.2 or 1.7, choosing between the two with a yardstick called QALY shortfall. The net effect is a higher, formula-driven willingness to pay for the patients who are worst off.

Key points#

• A cost-effectiveness threshold is the most a payer will spend per unit of health before the spending starts to displace more benefit than it buys.
• Severity weighting deliberately breaks the assumption that a year of health restored to a mild case is worth the same as one restored to a dying young patient.
• NICE ranks severity with QALY shortfall, measured two ways (absolute and proportional), and applies whichever gives the larger multiplier.
• A 1.7 multiplier under a 30,000 pound ceiling lets the effective price reach roughly 51,000 pounds per unweighted QALY.
• The modifier replaced NICE's older end-of-life rule in 2022 and was tuned to shift priorities rather than spend more overall.

Start with the payer's problem#

Every publicly funded system faces the same arithmetic. Its budget is fixed, so money spent on one therapy is money not spent on another. To keep the accounting honest, most systems price health in a common currency: the quality-adjusted life year (QALY), which folds together how much longer a patient lives and how well they live during that time. A new treatment earns an incremental cost-effectiveness ratio, its extra cost divided by the extra QALYs it delivers, and that ratio is judged against a threshold.

The threshold is not a shopping budget. It represents the point at which paying more for a new therapy would push aside more health elsewhere in the system than the therapy itself creates. NICE has used a band of roughly 20,000 to 30,000 pounds per QALY for two decades. In December 2025 it confirmed that this band will move up to 25,000 to 35,000 pounds per QALY once the regulations allow, expected in April 2026, its first threshold change in twenty years.

The equity problem a flat threshold ignores#

A single flat threshold carries a hidden assumption: that one healthy year is worth the same no matter who receives it. A year handed back to someone with a mild, self-resolving complaint counts exactly as much as a year handed back to a young person facing early death. Many people find that trade unfair. The intuition is that a benefit matters more when it reaches someone who is already worse off.

Severity weighting is the machinery that writes that intuition into policy. Rather than leaving it to case-by-case sympathy, it applies a defined multiplier to the health gains of treatments for severe conditions, making the preference explicit, consistent, and open to challenge.

Measuring who is worst off with two rulers#

To apply a multiplier fairly, the system needs an objective severity score. NICE uses QALY shortfall: the gap between the lifetime quality-adjusted life expectancy a patient can expect under current care and what a similar person of the same age and sex expects in the general population. The size of that gap decides the multiplier, and there are two legitimate ways to size it.

Absolute shortfall is the raw count of quality-adjusted years lost. It measures the total quantity of health forgone. Because younger patients have more life ahead of them to lose, this ruler tends to light up when a severe condition strikes early. In the peer-reviewed NICE record, every decision that crossed the highest absolute threshold involved patients under age 20.

Proportional shortfall is the fraction of remaining healthy life a disease erases, the years lost divided by the years a person would otherwise have had. It measures how completely an illness takes away what was left, so it can flag severe disease in older patients who start with fewer baseline years but stand to lose nearly all of them. In the same NICE data, proportional shortfall peaks near age 60.

NICE calculates both and keeps whichever produces the larger weight. The cut-offs stack up like this:

• Absolute shortfall under 12 QALYs, or proportional shortfall under 0.85: no uplift, weight 1.0.
• Absolute shortfall of 12 to 18, or proportional shortfall of 0.85 to 0.95: weight 1.2.
• Absolute shortfall of 18 or more, or proportional shortfall of 0.95 or more: weight 1.7.

Running both rulers side by side is itself a value choice, and you can see what it protects: the young patient staring at decades of lost life, and the older patient losing almost everything that remained. Neither definition of severity is forced to win.

Turning a multiplier into money#

The modifier never touches the threshold. It multiplies the QALYs a treatment delivers, which lowers the cost per weighted QALY, which is the same thing as raising the price the payer will accept. Run one figure through and you can see the lever. Under the current 30,000 pound ceiling, a 1.7 weight lets a treatment for the most severe conditions be judged cost-effective up to about 51,000 pounds per unweighted QALY. A 1.2 weight raises that effective ceiling to roughly 36,000 pounds. Severity, once translated into a shortfall number, becomes a direct dial on willingness to pay.

What the modifier replaced#

From 2009, NICE ran a separate end-of-life provision. It gave extra weight, on the order of 1.7 times, to therapies that extended the lives of patients with a short life expectancy (generally under 24 months) by at least three months. The rule was narrow, and in practice it rewarded one clinical shape: terminal illness paired with a life-extending drug. Analysis of the NICE record shows it applied almost entirely to older patients, with a mean age close to 59.

The 2022 methods manual retired that provision and installed the shortfall-based modifier in its place. The goal was a broader and more consistent basis for extra value, one that could recognize a crushing chronic disease in a young person, not only a terminal cancer in an older one. The switch was also calibrated to be roughly neutral for the overall budget. Mean weights before and after were statistically indistinguishable, near 1.12. In other words, severity weighting rearranged which conditions get priority rather than simply opening the purse.

Where the judgment still bites#

The modifier's great strength is that it drags an ethical preference into the open where you can audit it. Its limitation is that the numbers inside it are still contested value choices dressed as thresholds. The Office of Health Economics has pointed out that NICE's severity cut-offs sit higher than those used elsewhere. The Netherlands treats a proportional shortfall of 0.70 as its top tier, and Norway anchors on undiscounted absolute shortfall above 20. Where a country draws its lines, and how steeply it tilts the scale, encodes a particular idea of fairness that preference research is still trying to pin down. So when a treatment is turned down as poor value, ask whose severity rules were doing the arithmetic. The mechanism is transparent. The values embedded in it remain a live argument.